TuHURA BIOSCIENCES, INC./NV Asset Acquisition Contingent Consideration Liability Current
TuHURA BIOSCIENCES, INC./NV (HURA) had Asset Acquisition Contingent Consideration Liability Current of $2.78 million as of 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent · last filed 2025-11-14
- 2025-09-30: Asset Acquisition Contingent Consideration Liability Current $2.78M.
- 2025-06-30: Asset Acquisition Contingent Consideration Liability Current $2.52M.
| Period end | Asset Acquisition Contingent Consideration Liability Current |
|---|---|
| 2025-09-30 | $2.78M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $2.52M 10-Q · filed 2025-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |